Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 8 | 13 | +0,67 % | ||
| AVADEL PHARMACEUTICALS | 7 | 6 | 0,00 % | ||
| BIOGEN | 4 | 54 | -2,01 % | ||
| LEXICON PHARMACEUTICALS | 3 | 4 | -4,68 % | ||
| NURIX THERAPEUTICS | 3 | 4 | 0,00 % | ||
| LIGAND PHARMACEUTICALS | 3 | 2 | +1,90 % | ||
| MODERNA | 2 | 16 | -1,23 % | ||
| PTC THERAPEUTICS | 2 | 4 | 0,00 % | ||
| LEXEO THERAPEUTICS | 2 | 3 | 0,00 % | ||
| MIRUM PHARMACEUTICALS | 2 | 1 | +0,90 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:06 | Morgan Stanley reports trading activity in Avadel Pharmaceuticals shares | 1 | Investing.com | ||
| 11:06 | BeOne Medicines stock rating reiterated at Market Outperform by Citizens | - | Investing.com | ||
| 10:58 | Morgan Stanley legt Handelsaktivitäten in Aktien von Avadel Pharmaceuticals offen | 1 | Investing.com Deutsch | ||
| 10:26 | ANAVEX LIFE SCIENCES CORP zündet jetzt den Turbo! | 2 | Maximilian Berger | ||
| 10:23 | 60 Prozent Aufwärtspotenzial?: BioNTech: Diese Gamechanger sind noch nicht im Kurs eingepreist! | 296 | wallstreetONLINE | © Foto: Sebastian Gollnow/dpa Für Anleger von BioNTech gab es 2025 nicht viel zu feiern. Auf Jahressicht hat die Aktie rund 15 Prozent verloren. Dabei sind die großen Innovationen im Krebsbereich noch... ► Artikel lesen | |
| 09:06 | Sanofi's Qfitlia and Cablivi get nod from China | 11 | Seeking Alpha | ||
| 08:30 | Morgen-Update: Biontech-Aktie im Fokus - wann platzt endlich der Knoten? | Hebelschein-Spekulant | |||
| 08:18 | Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating | 1 | Investing.com | ||
| 08:07 | Genmab A/S: Genmab to Hold 2025 R&D Update and ASH Data Review Meeting | 5 | GlobeNewswire (USA) | ||
| 08:06 | BERENBERG stuft Biontech auf 'Buy' | 573 | dpa-AFX-Analyser | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Biontech von 150 auf 155 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Die Fortschritte in der Onkologie-Forschungspipeline... ► Artikel lesen | |
| 07:48 | Sanofi: NMPA In China Approves Qfitlia And Cablivi | 168 | AFX News | PARIS (dpa-AFX) - Sanofi (SNY) announced the National Medical Products Administration in China has approved two Sanofi medicines for rare hematologic diseases: Qfitlia or fitusiran for hemophilia... ► Artikel lesen | |
| 07:36 | Immunovant Inc.: Immunovant Announces Pricing of $550 Million Common Stock Financing | 1 | GlobeNewswire (USA) | ||
| 07:10 | Sanofi: Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases | 289 | GlobeNewswire (Europe) | Sanofi's Qfitlia and Cablivi approved in China, expanding care for rare diseases
Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six... ► Artikel lesen | |
| 06:54 | Guardant Health, Inc.: Guardant Health und Policlinico Gemelli starten internen Flüssigbiopsie-Testdienst in Italien | 170 | Business Wire | Führendes europäisches Krankenhaussystem beginnt mit dem Angebot von Flüssigkbiopsie-Tests vor Ort auf Basis der proprietären Guardant360 CDx-Technologie
Guardant Health, Inc. (Nasdaq: GH), ein... ► Artikel lesen | |
| 02:18 | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | 4 | Investing.com | ||
| 00:31 | Why Dyne Therapeutics Stock Was a Big Winner on Wednesday | 2 | The Motley Fool | ||
| 00:06 | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mi | 59 NORTH COMMUNICATIONS: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | 12 | Cision News | ||
| Mi | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mi | Nanexa AB: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | 74 | GlobeNewswire (Europe) | The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments... ► Artikel lesen |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .